First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...
Tandem Diabetes Care, Inc.’s Control-IQ+ Technology, used with the t:slim and Mobi insulin pumps, becomes the second AID ...
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes.
Control-IQ+ automated insulin delivery technology from Tandem Diabetes Care cleared by FDA for people with type 2 diabetes.
“Our internal and external experts all believe that the implementational time frame, while not as fast as we had hoped, are ...
Staff units evaluating high-tech surgical robots and insulin-delivery systems were gutted by Trump layoffs even though ...
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...
A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...
The US FDA has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results